SUBSCRIBE
SUBSCRIBE

Phase I

Drug Development
National Center for Research Resources (NCRR) Launches National Network to Connect Investigators Based at Minority Institutions: $9.5 Million Grant
July 25, 2007
 · 
1 min read
Drug Development
Informed Consent ‘Not up to Scratch’
July 19, 2007
 · 
1 min read
Drug Development
University of Rochester Doing World’s First Trial of Pill Targeting Lymphoma
July 19, 2007
 · 
1 min read
Drug Development
Clinical Drug Trials Put Thais ‘at Risk’
July 18, 2007
 · 
1 min read
Drug Development
Clinical Trials on a Naive Indian Audience Zoom
July 18, 2007
 · 
1 min read
Drug Development
Britain Adopts More Stringent Rules for Phase I Trials of High-Risk Compounds
June 27, 2007
 · 
1 min read
Drug Development
The Day In Review: Targeted Genetics Corporation Soars While Biotech Falls
November 27, 2006
 · 
1 min read
Drug Development
The Day In Review: Pfizer Inc. Buys Embrex For $155 Million
November 16, 2006
 · 
1 min read
Drug Development
The Day In Review: Merck & Co., Inc. Buys Sirna Therapeutics, Inc. For $1.1 Billion
October 30, 2006
 · 
1 min read
Drug Development
Cell Therapeutics, Inc. Pops On Old News
August 23, 2006
 · 
1 min read
Load More
PRESS RELEASES
Press Releases
D3 Bio Receives U.S. FDA Clearance for Two IND Applications, Enabling Phase 1 Trial of D3S‑003 and Phase 2 Combination Study of Elisrasib (D3S‑001) with D3S‑002
January 19, 2026
 · 
3 min read
Press Releases
Corvus Pharmaceuticals to Announce Results from Cohort 4 of Placebo-Controlled Phase 1 Clinical Trial of Soquelitinib for Atopic Dermatitis
January 19, 2026
 · 
3 min read
Press Releases
OrsoBio Announces Nature Medicine Publication Establishing Clinical and Mechanistic Validation of First-in-Class LXR Inverse Agonist TLC-2716 for the Treatment of Serious Metabolic Diseases
January 16, 2026
 · 
4 min read
Press Releases
Nouscom Highlights Potential of NOUS-209 to Intercept Cancer in Lynch Syndrome Carriers in Seminal Nature Medicine Publication
January 16, 2026
 · 
8 min read
Press Releases
CASI Pharmaceuticals Announces Approval of Clinical Trial Application by China NMPA for Phase 1 / 2 Study of CID-103 for Renal Allograft Antibody-Mediated Rejection (AMR)
January 16, 2026
 · 
7 min read
Press Releases
AAVantgarde Completes Enrollment in LUCE-1 Phase 1/2 Clinical Trial of AAVB-081 for Usher Syndrome Type B-associated Retinitis Pigmentosa
January 16, 2026
 · 
4 min read
Press Releases
Caldera Therapeutics Launches with $112.5 Million and Announces First Subjects Dosed in Phase 1 Trial of First-In-Class Bispecific Antibody CLD-423 for Inflammatory Bowel Disease
January 15, 2026
 · 
2 min read
Press Releases
Solid Biosciences Provides 2026 Outlook Underscoring Neuromuscular and Cardiac Pipeline Momentum and Expanded Access to Next-Generation Capsid AAV-SLB101
January 14, 2026
 · 
10 min read
Press Releases
Marea Therapeutics Unveils Positive Topline Phase 1 Data for MAR002 in Acromegaly; Demonstrates Potential for Best-in-Disease Efficacy and Dosing Profile
January 13, 2026
 · 
6 min read
Press Releases
Pasithea Therapeutics Provides Outlook on PAS-004 Clinical Programs and Data Release Timelines
January 13, 2026
 · 
4 min read
Press Releases
Immunofoco Presents Phase I/IIa Data of IMC002 at ASCO GI 2026, Highlighting a Durable Complete Response Beyond One Year and a 66.7% ORR in Advanced GC/GEJ
January 13, 2026
 · 
5 min read
Press Releases
AbCellera Announces First Patients Dosed in Phase 2 Portion of its Phase 1/2 Clinical Trial of ABCL635 for the Treatment of Vasomotor Symptoms Due to Menopause
January 13, 2026
 · 
4 min read
Press Releases
CASI Pharmaceuticals Announces Update and Additional Results from Phase 1 Study of CID-103 in Adult Patients with Chronic Immune Thrombocytopenia
January 13, 2026
 · 
9 min read
Press Releases
BioAge Announces Additional Positive Interim Phase 1 Data for BGE-102, a Novel Brain-Penetrant NLRP3 Inhibitor, Demonstrating Potential for Best-in-Class hsCRP Reduction in Participants with Elevated Cardiovascular Risk
January 13, 2026
 · 
9 min read
Press Releases
Disc Medicine Highlights Recent Achievements and Key Business Objectives and Milestones for 2026
January 13, 2026
 · 
7 min read
Press Releases
Encoded Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to ETX101 for the Treatment of Dravet Syndrome
January 12, 2026
 · 
3 min read
Press Releases
Kivu Bioscience Announces First Patient Dosed in Phase 1 Trial of KIVU-107 Next-Generation PTK7-Targeting ADC for Advanced Solid Tumors
January 12, 2026
 · 
1 min read
Press Releases
CARsgen and Dispatch Bio Announce Clinical Collaboration to Evaluate Flare Platform and Zevor-cel in Solid Tumors
January 12, 2026
 · 
5 min read
Press Releases
IN8bio Presents Updated Phase I/II Data Demonstrating Meaningful and Durable Survival Improvements in Newly Diagnosed Glioblastoma
January 12, 2026
 · 
5 min read
Press Releases
Recludix Pharma Announces Dosing of First Subjects in a Phase 1 Study of REX-8756, a Potent and Selective Oral STAT6 Inhibitor, and Achieves Associated $20 Million Milestone Payment Under Collaboration with Sanofi
January 12, 2026
 · 
4 min read
Load More